Duchenne Muscular Dystrophy (DMD) is a muscle degeneration and is a genetic disorder which is X-linked recessive. However, it is also inherited from parents or caused due to a new mutation. There are various therapies and drugs to control DMD, however, there is still no cure for duchenne muscular dystrophy.
Major driving factors in the global duchenne muscular dystrophy market are the introduction of novel drugs and therapies, disease-modifying therapies, strong support from various companies for drug development and support from patient advocacy groups on the regulatory approval process. Moreover, mutation-specific therapies are likely to emerge as a major breakthrough in the duchenne muscular dystrophy treatment. Drug developers are also focusing on developing new drugs and therapies targeting newborns, young infants and also the last-stage DMD patients. In the last few years, there has been rapid development in the duchenne muscular dystrophy therapeutics. However, there is still a large number of patients who are not able to benefit from therapies and drugs due to its high cost and lack of awareness.
Get Enquiry More About This Report: http://www.marketgrowthanalysis.com/reports/sample/211
Duchenne Muscular Dystrophy (DMD) is a type of muscular disorder due to which most of the people are unable to walk at a very early stage and the affected muscles look larger due to the fat content. The symptoms include muscle weakness, difficulty in walking and breathing and intellectual disability. Although, the treatment to control and reduce the signs and symptoms is available, yet there is no cure for DMD. Key players in the market are also trying to spread awareness about DMD along with the investment in finding a treatment for the disease. Meanwhile, human clinical trials are also underway to find out effective therapy.
Various pharmaceutical companies and organizations are increasingly investing in the research and development activities to come up with an effective treatment for duchenne muscular dystrophy. Meanwhile, there is an ongoing research on gene therapy, exon skipping drugs, and stem cell therapy to treat duchenne muscular dystrophy in a better way. Current pharmacological interventions for duchenne muscular dystrophy include approaches to mitigate downstream and secondary pathological mechanisms and solutions targeting primary defect. Patients with DMD are not able to produce a protein known as dystrophin. Hence, a variety of new medications are being developed to replace dystrophin. Moreover, new therapies aim to repair muscle damage caused due to the absence of dystrophin. However, delay in diagnosis and the high cost of treatment and drugs are some of the factors restricting the growth of the market.
The global duchenne muscular dystrophy market is segmented into therapy, distribution channel, product type, and region. The product type is further segmented into corticosteroids, NSAIDs, and other products. Among these, corticosteroids are likely to witness the highest growth during the forecast period. By the end of 2026, corticosteroids are estimated to bring in more than US$ 9,000 million revenue.
Based on the distribution channel, the global duchenne muscular dystrophy market segmentation includes online pharmacies, retail pharmacies, and hospital pharmacies. Hospitals pharmacies are expected to be the largest distributors in the duchenne muscular dystrophy market. Hospital pharmacies are anticipated to exceed US$ 6,000 million revenue towards the end of 2026.
Get Request for Toc: http://www.marketgrowthanalysis.com/reports/toc/211
On the basis of therapy, the market segmentation includes Exon Skipping Approach, Mutation Suppression, and other therapies. Mutation suppression therapy is expected to witness strong growth throughout the forecast period. By the end of 2026, mutation suppression therapy is estimated to bring in more than US$ 6,400 million revenue.
Europe is expected to be the dominating region in the global duchenne muscular dystrophy market during the forecast period. Owing to the high rate of people suffering from duchenne muscular dystrophy, Europe is witnessing the growth in adoption of treatment for muscular dystrophy. Also, various treatments are approved or under review to treat duchenne muscular dystrophy in Europe. This is also one of the reasons for the growth of the market in Europe.
Some of the players in Duchenne Muscular Dystrophy Treatment Market are Bristol-Myers Squibb(U.S), FibroGen, Inc (U.S), ITALFARMACO S.p.A. (Italy), Catabasis Pharmaceuticals, Inc.(U.S) , NS Pharma, Inc. (U.S), Marathon Pharmaceuticals, LLC (U.S), ReveraGen BioPharma, Inc. (U.S), Pfizer (U.S), Summit Therapeutics plc (U.K), Taiho Pharmaceutical Co (Japan), Sarepta Therapeutics (U.S), Inc., Santhera Pharmaceuticals, PTC Therapeutics (Switzerland)
Full View of Report Description: http://www.marketgrowthanalysis.com/duchenne-muscular-dystrophy-treatment-market
Market Growth Analysis is one of the leading digital services provider and a result-oriented company based in Malaysia. We are a team of enthusiastic-driven individuals with top notch skills in SEO, Market research. Market Growth Analysis is a one stop shop to all your business needs. We help you thrive and succeed. We provide research solution.
Our digital and enterprise research assurance solutions are ideal for Automotive & Transportation, Electronics & Semiconductor, Chemicals & Materials, Healthcare, Pharmaceuticals & Medical Devices, Food & Beverage and Industrial Automation as well as all type of other leading industries verticals. We offer a vast line of in-depth study of industry trends including customized & client oriented specific requirement.
Our unique digital platform provides the services across the quality assurance research lifecycle on a 24X7 basis and delivers an unparalleled end-user experience for ‘mission critical’ products.
For any business solution, all you have to do is just ask and Market Growth Analysis will have a curated solution for you.
Unit 15A/7, capsquare residence,
NO.02 persiaran capsquare,
kuala lumpur, Malaysia
Postcode - 5000
However, it is also inherited from parents or caused due to a new mutation.
There are various therapies and drugs to control DMD, however, there is still no cure for duchenne muscular dystrophy.Major driving factors in the global duchenne muscular dystrophy market are the introduction of novel drugs and therapies, disease-modifying therapies, strong support from various companies for drug development and support from patient advocacy groups on the regulatory approval process.
The symptoms include muscle weakness, difficulty in walking and breathing and intellectual disability.
Meanwhile, human clinical trials are also underway to find out effective therapy.Various pharmaceutical companies and organizations are increasingly investing in the research and development activities to come up with an effective treatment for duchenne muscular dystrophy.
Moreover, new therapies aim to repair muscle damage caused due to the absence of dystrophin.
Hospitals pharmacies are expected to be the largest distributors in the duchenne muscular dystrophy market.
Market Overview-The global duchenne muscular dystrophy treatment market size is expected to gain momentum owing to the increasing awareness regarding the efficacy of the treatment among people during the forecast period.
For instance, according to the National Organization of Rare Disorder (NORD), around one in every 3,500 male births suffers from DMD.
It is characterised by weakness and wasting (atrophy) of the pelvic muscles, which is followed by involvement of the shoulder muscles.Request a Sample Copy of the Research ReportCOVID-19 Impact-Economic Impact Due to Covid-19 to Hinder GrowthThe market for duchenne muscular dystrophy treatment is a vibrant industry with many prospects for growth, but the present COVID-19 conditions have produced uncertainty in forecasts, revisions in short-term planning goals, and an emphasis on near-term cost management and long-term complexity management.Growth in the market varied greatly in 2020, as firms swiftly aligned their strategies to the existing market conditions.To get to know more about the short-term and long-term impact of COVID19 on this market, please visit:https://www.fortunebusinessinsights.com/industry-reports/duchenne-muscular-dystrophy-dmd-treatment-market-101863Segments-By treatment, the market for duchenne muscular dystrophy treatment is segmented into molecular therapies, steroid therapies, non-steroidal anti-inflammatory drugs, and others.
Finally, by geography, the market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.Quick Buy Duchenne Muscular Dystrophy Treatment MarketWhat does the Report Include?The report for duchenne muscular dystrophy treatment offers any detail that is crucial for scaling business in the following years is provided to the market.
These initiatives are likely to favor the adoption of the product worldwide.REGIONAL INSIGHTSIncreasing Investment in R Activities to Promote Growthin North AmericaNorth America is expected to hold the largest global duchenne muscular dystrophy treatment market share during the forecast period.
Moreover, the United States has dominated the regional market and is expected to maintain its lead backed by growing focus on clinical studies.Europe is anticipated to hold a significant position in the market.
